West Nile virus detected in Toronto
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Why Novo Nordisk Stock Bumped Higher on Friday
Key Points The Federal government might boost its support of weight-loss drugs soon. According to a media report, it's contemplating a five-year, experimental program that would subsidize their costs for qualifying patients. 10 stocks we like better than Novo Nordisk › Unexpected news of a potential support program from the federal government boosted the share prices of weight-loss drug developers on Friday. The poster boy for that still rather small group, Wegovy/Ozempic maker Novo Nordisk (NYSE: NVO), understandably saw a stock price lift that day. It rose by more than 2%, contrasting well with the 1.6% slide of the S&P 500 index. Federal help for obesity drugs? That news came from The Washington Post, which published an article stating that the Trump administration is planning an experimental program that would cover the costs of such medications. Citing documents from the Centers for Medicare and Medicaid Services (CMS) it had obtained, the newspaper said the plan would be implemented by state Medicaid administrations. It would also be utilized by Medicare Part D insurance plans. These entities would be allowed to cover weight-loss drugs for qualifying patients. At the moment, Medicare generally covers such treatments for patients who suffer from type 2 diabetes. Both Novo Nordisk's Wegovy and rival Eli Lilly 's Zepbound are essentially versions of predecessor diabetes drugs. Some private insurance plans cover obesity medications. The Post wrote that the experimental program will last for five years. Massive potential impact Novo Nordisk hasn't yet commented on the article, but we can be sure the company is excited about the prospect. Combined, Medicare and Medicaid are immense programs. Even if only a few states are willing to cover weight-loss treatments through them, the company could experience a surge in sales. For the stock's investors, this is a potentially very impactful development well worth monitoring. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
CTV News
3 hours ago
- CTV News
Liberal U.S. states sue Trump over transgender care ban
The Pride flag seen at Windsor, Ont. on Aug. 1, 2025. (Gary Archibald/CTV News Windsor) A coalition of liberal U.S. states on Friday said it was suing U.S. President Donald Trump's administration over an order to prevent clinics providing gender-affirming care to children. The lawsuit, brought by officials from California and 15 other states, as well as the District of Columbia, challenges an executive order that denounces the treatment as 'chemical and surgical mutilation.' The order, which Trump signed in January, calls on the U.S. Department of Justice (DoJ) to investigate providers who offer such treatment, even in states where it is legal. 'The President and his Administration's relentless attacks on gender-affirming care endanger already vulnerable adolescents whose health and well-being are at risk,' California's Attorney General Rob Bonta said. 'Their demands that our healthcare providers discriminate against transgender individuals and deny them access to medically-necessary healthcare is cruel and irresponsible.' The DoJ said last month it had issued more than 20 subpoenas to doctors and clinics providing treatment to adolescents. U.S. Attorney General Pam Bondi said at the time that 'medical professionals and organizations that mutilated children in the service of a warped ideology will be held accountable.' The lawsuit, filed in a U.S. District Court in Massachusetts, argues that the administration's actions have no legal basis and should be declared unlawful. 'These actions have created a chilling effect in which providers are pressured to scale back on their care for fear of prosecution, leaving countless individuals without the critical care they need and are entitled to under law,' said Bonta. LGBTQ+ rights have become a divisive subject in the United States, where Trump rode a wave of public support for his crusade against so-called 'woke ideology.' In his first days in office, Trump declared the federal government would recognize only two genders -- men and women -- and has targeted transgender people in a slew of other orders. In February, he issued an executive order aimed at banning transgender athletes, allowing federal agencies to halt funding to any institution that does not consider birth-assigned genders in determining sex. The lawsuit groups California with New York, Massachusetts, Illinois, Connecticut, Delaware, Hawaii, Maine, Maryland, Michigan, Nevada, New Jersey, New Mexico, Rhode Island, Wisconsin, Pennsylvania and the District of Columbia. It is the latest legal effort from a coalition of Democratic-run states aimed at pushing back at what liberals see as overreach by the Trump presidency.
Toronto Star
4 hours ago
- Toronto Star
Judge allows the National Science Foundation to withhold hundreds of millions of research dollars
NEW YORK (AP) — The National Science Foundation can continue to withhold hundreds of millions of dollars from researchers in several states until litigation aimed at restoring it plays out, a federal court ruled Friday. U.S. District Judge John Cronan in New York declined to force the NSF to restart payments immediately, while the case is still being decided, as requested by the sixteen Democrat-led states who brought the suit, including New York, Hawaii, California, Colorado and Connecticut.
